NEW ORLEANS — In this video from the American Academy of Ophthalmology meeting, Sunir J. Garg, MD, FACS, FASRS, discusses what has been learned from phase 3 data on two FDA-approved treatments for geographic atrophy.
Garg, of Wills Eye Hospital, noted that with pegcetacoplan, patients with nonsubfoveal geographic atrophy responded to treatment better that patients with subfoveal lesions. In addition, over time, both Syfovre (pegcetacoplan injection, Biogen) and Izervay (avacincaptad pegol intravitreal solution, Astellas) showed additive benefit of treatment at 12 months, 18 months and 24